The Europe Breast Cancer Screening Market was valued at USD 1.12 billion in 2024 and is predicted to reach USD 2.43 billion by 2033, growing at a CAGR of 9.02% from 2025 to 2033. The market is driven by increasing awareness about early cancer detection, advancements in screening technologies, and government initiatives promoting regular breast cancer screenings. The rising prevalence of breast cancer and improved access to healthcare facilities further contribute to market growth.
In Europe, breast cancer screening programs are widely promoted by governments and healthcare organizations. Many countries have national screening programs offering routine mammograms for women over a certain age, typically 50 to 74 years. The popularity of screening has grown due to increasing awareness, better healthcare infrastructure, and technological advancements. With the rise in breast cancer cases, European countries continue to expand access to screening, ensuring more women undergo regular check-ups. AI-assisted mammography and portable screening devices are enhancing early detection capabilities. As awareness and accessibility improve, the demand for advanced screening techniques continues to rise across Europe.
Europe Breast Cancer Screening Market Outlook
Breast cancer screening involves medical tests and imaging techniques to detect breast cancer at an early stage, often before symptoms appear. The most common screening methods include mammography, ultrasound, MRI, and genetic testing for high-risk individuals. Early detection significantly improves treatment success rates and survival rates by enabling timely interventions.In Europe, breast cancer screening programs are widely promoted by governments and healthcare organizations. Many countries have national screening programs offering routine mammograms for women over a certain age, typically 50 to 74 years. The popularity of screening has grown due to increasing awareness, better healthcare infrastructure, and technological advancements. With the rise in breast cancer cases, European countries continue to expand access to screening, ensuring more women undergo regular check-ups. AI-assisted mammography and portable screening devices are enhancing early detection capabilities. As awareness and accessibility improve, the demand for advanced screening techniques continues to rise across Europe.
Growth Drivers in the Europe Breast Cancer Screening Market
Government Initiatives and Awareness Programs
European governments actively promote breast cancer screening through national programs and awareness campaigns. Countries like the UK, Germany, and France offer free or subsidized mammograms for women aged 50-74. Organizations such as the European Breast Cancer Coalition advocate for early detection, ensuring increased participation in screening programs. These initiatives help drive demand for screening services and technologies, leading to market expansion. The EU is actively combating breast cancer through its Beating Cancer Plan, part of the European Health Union strategy. In 2022, updated screening guidelines for breast, colorectal, and cervical cancer were adopted, aiming to offer screening to 90% of eligible populations across the EU for improved prevention, treatment, and quality of life.Advancements in Screening Technologies
The adoption of digital mammography, AI-driven diagnostics, and 3D tomosynthesis has improved early breast cancer detection. AI-powered imaging systems enhance accuracy, reducing false positives and negatives. Europe is at the forefront of integrating these innovations into routine screenings, making advanced methods more accessible. As hospitals and diagnostic centers upgrade their equipment, the demand for cutting-edge screening technologies continues to rise. Mar 2025, GE HealthCare launched Invenia™ Automated Breast Ultrasound (ABUS) Premium, a 3D ultrasound featuring advanced AI to enhance supplemental screening and streamline exam readings for patients with dense breasts.Rising Breast Cancer Incidence Rates
With increasing breast cancer cases across Europe, there is growing urgency for widespread screening programs. The European Cancer Information System (ECIS) reports that breast cancer remains the most common cancer among women in Europe. The aging population and lifestyle factors contribute to higher risk, making routine screening essential. This demand fuels investments in screening infrastructure and services. Breast cancer is the most common cancer in women in the WHO Europe region with an estimated incidence of 604,900 in 2022.Challenges in the Europe Breast Cancer Screening Market
High Cost of Advanced Screening Technologies
Despite advancements, the high cost of MRI and 3D mammography remains a barrier. Not all healthcare facilities can afford the latest screening equipment, limiting access in some regions. In countries with underfunded healthcare systems, affordability issues prevent widespread adoption of advanced screening methods, leading to disparities in early detection.Screening Coverage Gaps and Accessibility Issues
Rural and underserved areas in Europe face challenges in accessing breast cancer screening. While urban centers have well-established programs, remote areas often lack the necessary healthcare infrastructure. Mobile screening units and telemedicine solutions are emerging to bridge the gap, but disparities still exist, particularly in Eastern Europe.Europe Breast Cancer Screening Population Market
The growing population of women eligible for breast cancer screening drives market growth. With an increasing focus on preventive healthcare, governments and private healthcare providers are expanding screening programs to cover younger women at high risk. Personalized risk assessments and genetic screening for BRCA1 and BRCA2 mutations are becoming more prevalent, improving early detection rates.Europe Breast Cancer Mammography Screening Market
Mammography remains the gold standard for breast cancer screening in Europe. The market is expanding due to rising government investments in screening infrastructure. Digital mammography and 3D tomosynthesis offer higher accuracy, leading to increased adoption. Many European countries conduct nationwide mammography screening, improving early diagnosis rates.Europe Breast Cancer MRI Screening Market
MRI is increasingly used for high-risk patients and dense breast tissue cases. Europe has seen rising adoption of breast MRI due to its superior sensitivity in detecting early-stage tumors. However, the high cost and limited availability of MRI machines restrict widespread use, primarily benefiting those with private healthcare access.Europe Breast Cancer Ultrasound Screening Market
Ultrasound is widely used as a supplementary screening method, especially for women with dense breast tissue. European healthcare systems are integrating automated breast ultrasound (ABUS) to improve screening accuracy. Ultrasound is particularly beneficial in cases where mammograms may be less effective, driving demand across hospitals and diagnostic centers.Germany Breast Cancer Screening Market
Germany has one of the most well-established breast cancer screening programs in Europe. The country offers nationwide mammography screening for women aged 50-69, funded by statutory health insurance. Technological advancements and AI-driven diagnostics are boosting the German market, making screenings more efficient and accessible. Feb 2023, Germany's deep tech startup Vara has recruited renowned radiologist Professor Katja Pinker-Domenig as its lead medical advisor to provide women worldwide with access to improved breast cancer screening that could save lives.France Breast Cancer Screening Market
France has a robust breast cancer screening initiative, with free mammography provided every two years for women aged 50-74. The French healthcare system emphasizes early detection, integrating AI and digital imaging. Continuous government efforts to improve awareness and participation rates contribute to market growth. March 2024, The Lunit company provides AI-powered solutions that can be used alongside cancer screenings and therapeutics. According to a press release,1 the deal will see Lunit providing the two territories with AI-powered radiology solutions that can be used with both chest x-rays and breast cancer detection.United Kingdom Breast Cancer Screening Market
The UK’s National Health Service (NHS) provides free mammograms to women aged 50-70. The NHS Breast Screening Programme is one of the largest in Europe, and recent expansions include AI-assisted diagnostics to enhance detection rates. The increasing adoption of digital screening technologies strengthens the market. Feb 2025, The UK government has launched a major trial to assess the effectiveness of AI in improving early breast cancer detection. Led by the Department of Health and Social Care (DHSC), the initiative involves nearly 700,000 individuals being screened at 30 sites across England, utilizing AI technologies to enhance diagnosis accuracy and efficiency.Netherlands Breast Cancer Screening Market
The Netherlands has a high participation rate in breast cancer screening, with government-funded programs covering women aged 50-75. Mobile screening units are widely used, improving access in rural areas. Dutch healthcare providers are increasingly adopting AI and personalized screening strategies, driving market growth. Oct 2023, Agendia NV, a leader in precision oncology for breast cancer, announced that the Dutch National Healthcare Institute (ZIN) has approved MammaPrint® for inclusion in the national health insurance basic package. This decision is based on MINDACT study data, confirming that MammaPrint meets reimbursement criteria. The approval targets women over 50 with hormone-positive, HER2-negative breast cancer and 0-3 involved lymph nodes (clinical high risk), marking a significant advancement in personalized care for breast cancer patients in the Netherlands.Europe Breast Cancer Screening Market Segment
Europe Breast Cancer Screening Market
- Mammography Screening Market
- MRI Screening Market
- Ultrasound Screening Market
Europe Breast Cancer Screening Population
- Mammography Screening Population
- MRI & Ultrasound Screening Population
Country
- United Kingdom
- France
- Germany
- Italy
- Spain
- Switzerland
- Norway
- Netherlands
The key players have been analyzed by:
- Overviews
- Key Persons
- Recent Developments
- Product Portfolio
- Revenue
Key Players Analyzed
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
Table of Contents
1. Introduction2. Research Methodology3. Executive Summary
4. Market Dynamics
5. Europe Breast Cancer Screening Population Analysis
6. Europe Breast Cancer Screening Market Analysis
7. Europe Breast Cancer Screening Population Share Analysis
8. Europe Breast Cancer Screening Market Share Analysis
9. United Kingdom
10. France
11. Germany
12. Italy
13. Spain
14. Switzerland
15. Norway
16. Netherlands
17. Porter’s Five Forces
18. SWOT Analysis
19. Company Analysis
Companies Mentioned
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
Methodology
In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.
Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.
Primary Research
The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:
- Validates and improves the data quality and strengthens research proceeds
- Further develop the analyst team’s market understanding and expertise
- Supplies authentic information about market size, share, growth, and forecast
The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:
- Chief executives and VPs of leading corporations specific to the industry
- Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
- Key opinion leaders (KOLs)
Secondary Research
The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Patent and regulatory databases for understanding of technical & legal developments
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic new articles, webcasts, and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | May 2025 |
| Forecast Period | 2024 - 2033 |
| Estimated Market Value ( USD | $ 1.12 Billion |
| Forecasted Market Value ( USD | $ 2.43 Billion |
| Compound Annual Growth Rate | 9.0% |
| Regions Covered | Europe |
| No. of Companies Mentioned | 6 |
